Abeona Therapeutics receives FDA Fast Track designation for its ABO-202 gene therapy

For the second time since April, Abeona Therapeutics Inc. (Nasdaq: ABEO), a clinical-stage biopharmaceutical company co-headquartered in Cleveland and New York, has received Fast Track designation from the U.S. Food and Drug Administration for one of its therapies.

Click here to read the complete article.

Story excerpt provided by Crain’s Cleveland Business.

Written by Scott Suttell.

Originally published June 18, 2019.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: